In a recent post on the IVI-sponsored Health Affairs featured blog series, Rachel Sachs summarizes Scott Gottlieb’s FDA Commissioner confirmation hearing and top-lines four areas of questioning: the drug approval process, the character of the FDA, the opioid epidemic, and soaring drug prices. Also notable for not being mentioned, Rachel is curious how Dr. Gottlieb will address the FDA’s relationship with other agencies, in particular the DHHS.

Read the full article here.

About the Health Affairs/IVI Featured Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.